SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+12.42%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$333M
AUM Growth
+$333M
(-1.9%)
Cap. Flow
-$32.9M
Cap. Flow
% of AUM
-9.87%
Top 10 Holdings %
Top 10 Hldgs %
56.09%
Holding
63
New
21
Increased
10
Reduced
17
Closed
13
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$14.2M |
| 2 |
Incyte
INCY
|
$8.56M |
| 3 |
Praxis Precision Medicines
PRAX
|
$8.33M |
| 4 |
Arcutis Biotherapeutics
ARQT
|
$7.56M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$7.06M |
Top Sells
| 1 |
Arcellx
ACLX
|
$18.4M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$17.2M |
| 3 |
Immunocore
IMCR
|
$11.5M |
| 4 |
Merck
MRK
|
$10.2M |
| 5 |
Immunovant
IMVT
|
$9.72M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Syndax Pharmaceuticals
SNDX
$1.41B
| $33.3M | 9.98% |
1,731,191
+319,015
| +23% | +$6.14M |
|
2
Roivant Sciences
ROIV
$8.15B
| $32M | 9.57% |
2,769,819
+57,078
| +2% | +$659K |
|
3
Merus
MRUS
$4.98B
| $21M | 6.3% |
421,222
+132,554
| +46% | +$6.62M |
|
|
4
Immunovant
IMVT
$2.56B
| $19.1M | 5.73% |
671,001
-340,878
| -34% | -$9.72M |
|
|
5
Arcutis Biotherapeutics
ARQT
$1.86B
| $16.5M | 4.95% |
1,778,318
+812,926
| +84% | +$7.56M |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $15.8M | 4.74% |
1,481,809
-13,238
| -0.9% | -$141K |
|
|
7
Bristol-Myers Squibb
BMY
$96B
| $14.2M | 4.26% |
+275,303
| New | +$14.2M |
|
8
Applied Therapeutics
APLT
$71M
| $13.2M | 3.96% |
1,554,586
-656,734
| -30% | -$5.58M |
|
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $10.9M | 3.27% |
213,815
-337,280
| -61% | -$17.2M |
|
10
Biohaven
BHVN
$1.63B
| $10.8M | 3.24% |
216,440
-16,815
| -7% | -$840K |
|
|
11
Praxis Precision Medicines
PRAX
$958M
| $10M | 3% |
174,034
+144,775
| +495% | +$8.33M |
|
|
AUTL
12
Autolus Therapeutics
AUTL
$399M
| $9.5M | 2.84% |
2,616,602
-46,130
| -2% | -$167K |
|
|
13
Incyte
INCY
$16.5B
| $8.56M | 2.56% |
+129,490
| New | +$8.56M |
|
14
Denali Therapeutics
DNLI
$2.23B
| $8.22M | 2.46% |
282,050
+31,040
| +12% | +$904K |
|
|
15
Day One Biopharmaceuticals
DAWN
$769M
| $7.06M | 2.11% |
+506,978
| New | +$7.06M |
|
|
SLRN
16
DELISTED
ACELYRIN
SLRN
| $6.5M | 1.95% |
+1,317,854
| New | +$6.5M |
|
17
Soleno Therapeutics
SLNO
$3.6B
| $6.22M | 1.86% |
+123,177
| New | +$6.22M |
|
18
Cabaletta Bio
CABA
$133M
| $6.03M | 1.81% |
1,278,444
+100,339
| +9% | +$474K |
|
19
Immatics
IMTX
$619M
| $5.13M | 1.54% |
449,735
-52,472
| -10% | -$599K |
|
20
Keros Therapeutics
KROS
$618M
| $5.05M | 1.51% |
+86,930
| New | +$5.05M |
|
|
21
Arcellx
ACLX
$3.85B
| $5.02M | 1.5% |
60,076
-220,633
| -79% | -$18.4M |
|
22
VistaGen Therapeutics
VTGN
$102M
| $4.9M | 1.47% |
1,846,792
-1,790
| -0.1% | -$4.75K |
|
23
Nurix Therapeutics
NRIX
$714M
| $4.56M | 1.37% |
203,015
-258
| -0.1% | -$5.8K |
|
24
TScan Therapeutics
TCRX
$102M
| $4.29M | 1.28% |
860,951
+15,882
| +2% | +$79.1K |
|
25
Zura Bio
ZURA
$133M
| $4.24M | 1.27% |
+1,044,168
| New | +$4.24M |
|